Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends

This article was originally published in The Pink Sheet Daily

Executive Summary

In shifting away from specific targets and non-statin add-on therapies, new ACC/AHA cholesterol guidelines support treatment of people at relatively low risk for events and more intensive therapy for those at higher risk.


Related Content

Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?
Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
Bad News/Good News For Cholesterol: Another Strike Against HDL, But Support For Stricter LDL Targets
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
2012 Wild Card: Will Guideline Revisions Drive Demand For Better Drugs?
Today’s Statin Debate Bears Lessons For Tomorrow’s Cholesterol Drugs
Statin Labeling Changes Include Class Warning About Glucose Effects
SEARCH Ends Badly For Simvastatin 80 Mg; FDA Restricts Use To Existing Patients
More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit
Crestor Label Lends Validity To Controversial C-Reactive Protein Test


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts